Johnson & Johnson will acquire Firefly Bio for $1 billion in cash, gaining access to Firefly’s “degrader antibody conjugates” platform. The deal is designed to complement J&J’s oncology pipeline and broaden its technology exposure as the company navigates patent-expiration pressures in existing therapies.